Home
Mesothelioma
What is Mesothelioma
Symptoms
and Diagnosis
Stages of Mesothelioma
Mesothelioma
Treatment
• Surgery
• Chemotherapy
• Radiotherapy
• Clinical Trials
• Palliative Care
Mesothelioma
Specialists
Treatment Centers
Mesothelioma News
|
|
Phase III Randomized Study of Radiotherapy in the Prevention of Metastatic
Skin Nodules Following Invasive Diagnostic Procedures in Patients With
Malignant Mesothelioma
Alternate Title
Radiation Therapy in Preventing Metastatic Cancer in Patients Who Have
Diagnostic Procedures to Identify Malignant Mesothelioma
Basic Trial Information
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: CRC-BOC-L52, EU-20033, NCT00006231
Objectives
-
Determine the efficacy of radiotherapy in the
prevention of metastatic skin nodules or tumor seeding following invasive
diagnostic procedures, such as chest drain insertion, pleural aspiration,
pleural biopsy, and thoracoscopy, in patients with malignant mesothelioma.
-
Determine whether the nodules that develop after
radiotherapy are symptomatic in these patients.
-
Compare the quality of life of patients treated
with radiotherapy vs standard care alone.
Entry Criteria
Disease Characteristics:
-
Histologically proven malignant pleural mesothelioma
by chest drain insertion, pleural aspiration, pleural biopsy, and/or
thoracoscopy within the past 3 weeks
Prior/Concurrent Therapy:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
Patient Characteristics:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Projected Accrual
A total of 44 patients (22 per arm) will be accrued for this study
within 2 years.
Outline
This is a randomized study.
Patients are randomized to 1 of 2 treatment arms.
-
Arm I: Patients receive radiotherapy on 3 consecutive
days beginning within 3 weeks after chest drain insertion, pleural
aspiration, pleural biopsy, or thoracoscopy and once the wounds have
healed.
-
Arm II: Patients receive standard supportive care
alone.
Quality of life is assessed at baseline, and then at 1, 2, 4, 6, 9,
and 12 months.
Patients are followed at 1, 2, 4, 6, 9, and 12 months.
Disclaimer
The purpose of most clinical trials listed in this database is to test
new cancer treatments, or new methods of diagnosing, screening, or preventing
cancer. Because all potentially harmful side effects are not known before
a trial is conducted, dose and schedule modifications may be required
for participants if they develop side effects from the treatment or
test. The therapy or test described in this clinical trial is intended
for use by clinical oncologists in carefully structured settings, and
may not prove to be more effective than standard treatment. A responsible
investigator associated with this clinical trial should be consulted
before using this protocol.
Published Results
O'Rourke N, Paul J, Hill J: Radiotherapy to mesothelioma drain sites
may not be worthwhile: interim report of a randomized study. Lung Cancer
29(suppl 2): 168, 2000
Trial Contact Information
Trial Lead Organizations
Cancer Research UK Clinical Trials Unit at the University of
Glasgow
Noelle O'Rourke, MD, Protocol chair
Ph: 0414-211-1738
Email: norourke@tinyworld.co.uk
Trial Sites and Contacts
Glasgow, Scotland:
Beatson Oncology Centre
Noelle O'Rourke, MD
Ph: 0414-211-1738
Gartnavel General Hospital
Andrew Peacock, MD
Ph: 44-141-211-3000
Stobhill General Hospital
R Jones, MD
Ph: 44-141-201-3000
|
|
| Request a Free Complete Email Information
Packet
|
|